Antimicrobial peptides are natural antibiotics that constitute a major part of the innate immunity in all organisms (33) . Many are positively charged, adopt an amphipathic structure when they are in contact with biological membranes (13, 16, 27, 29) , and act through a non-receptor-mediated membrane lytic mechanism (2, 30) . However, recent studies suggest other targets as well (9) . Furthermore, because they act rapidly against the bacterial membrane, with a direct and destructive mode of action, they can escape the mechanisms involved in drug resistance, although there is some evidence that specific resistance might occur (14, 31) . Therefore, antimicrobial peptides have been extensively studied for their potential use as antibiotics with new targets (3, 6, 13, 22, 25, 33) .
Despite their advantages, systemic administration of antimicrobial peptides is difficult because they are inactivated by blood components. Therefore, the in vivo activities of membrane-active antimicrobial peptides have been reported in only a limited number of studies, and they were mainly administered intraperitoneally (4, 5, 7, 11, 15, 18, 23, 28) . To overcome this limitation, we have developed a new family of nonhemolytic DL-amino acid antimicrobial peptides (diastereomers) which maintain their full activities in serum (17, 20, 26) . In the present study we compared the in vitro activities of an all-Lamino-acid antimicrobial peptide and its diastereomer after systemic administration to bacteria-infected mice.
We synthesized an amphipathic all-L-amino-acid peptide (amphipathic-L) and its diastereomer (amphipathic-D) with the sequences LKLLKKLLKKLLKLL-NH 2 (molecular weight, 1,804) and LKLLKKLLKKLLKLL-NH 2 (underlined amino acids are the D enantiomers), respectively. The synthesis protocol was described previously (20) . Treatment with trypsin (2 h) completely cleaved amphipathic-L, whereas amphipathic-D was protected by ϳ50%. Furthermore, serum inactivated amphipathic-L, and therefore, most experiments were performed only with the diastereomer.
The peptides were first investigated in vitro for their antibacterial and bactericidal activities against gentamicin-sensitive Pseudomonas aeruginosa ATCC 27853 and a gentamicinresistant strain of Acinetobacter baumannii resistant primarily due to extended-spectrum beta-lactamase production (8) isolated from the blood cultures of a patient with nosocomial pneumonia, as well as against their corresponding spheroplasts. The assay was done in sterile 96-well plates by a dilution assay protocol described in detail elsewhere (17, 20) . The antibacterial activities were expressed as the MICs, i.e., the concentrations at which 100% inhibition of growth was observed after 18 to 20 h of incubation. A similar protocol was used, however, with the peptides dissolved in 30% human blood serum. Table 1 shows the biological activities of the peptides. Time-kill experiments (19) of amphipathic-D at its MIC against A. baumannii were performed and showed fast kinetics (Fig.  1A) . Similar results were obtained with P. aeruginosa.
In order to test whether amphipathic-D obtained its biological function through bacterial plasma membrane perturbation, we performed transmembrane potential-depolarizing experiments with the intact bacteria and their spheroplasts using the potential sensitive dye diS-C 3 -5 (the protocol has been described in detail elsewhere [20, 32] ). Figure 1B and C shows the concentration-and time-dependent dissipations of the transmembrane potential of A. baumannii, respectively. These data reveal a direct correlation between the kinetics of potential depolarization and killing of bacteria (Fig. 1A) , which supports the notion that the bacterial membrane is a major target for the peptides. Furthermore, the finding of similar activities against the cell wall-deficient spheroplasts suggests a minor role for the bacterial wall in the killing mechanism. Similar results were obtained with P. aeruginosa and therefore are not shown.
Confocal fluorescence microscopy (Olympus FV500 confocal laser scanning microscope) was used to visualize the localization of rhodamine-labeled amphipathic-D (labeled specifically at the N terminus by a protocol described before [21] ) when it was bound to P. aeruginosa (data not shown). Interestingly, the peptide initially bound primarily mostly to the septums of two separating bacteria, but it finally became equally distributed within the bacterial cytoplasm. Transmission electron microscopy (the protocol is described elsewhere [1] ) revealed damage to the bacterial cell wall (data not shown).
Most importantly, the peptides were tested intravenously for their activities against female CD1 mice that were infected with inocula of 10 6 CFU of bacteria (n ϭ 8). Treated mice were systemically injected with a daily dose of 6 mg/kg of body weight, divided into two injections of 3 mg/kg at 12-h intervals, starting 1 h after inoculation. The results, shown in Fig. 2 , demonstrate that only the diastereomer cured mice infected with both types of bacteria. Inoculated mice became weak and less active as early as 1 day after inoculation (and treatment). The maximum loss of body weight occurred on day 2. Physical improvement of diastereomer-treated mice was noted on day 3, and 5 days after the bacterial challenge, all the survivors displayed normal activity and had recovered their initial weight. Nearly all deaths occurred between days 2 and 3 postinoculation with P. aeruginosa and between days 3 and 4 postinoculation with gentamicin-resistant A. baumannii. In order to decrease the influence of the immune system, all the mice were rendered transiently neutropenic by intravenously injecting 150 and 100 mg of cyclophosphamide per kg on days 0 and 3, respectively (12, 15) .
The acute toxicities of the two peptides were also examined by intravenously injecting each mouse (n ϭ 8) with two doses per day of a 0.25-ml solution containing peptide at 3 mg/kg (no mortality), 6 mg/kg (20% mortality), or 9 mg/kg (80% mortality) for 5 days. Note that no mortality was observed after doses of 6 mg/kg dissolved in 0.9 ml of buffer were injected. Blood samples were taken from the mice a week after the injection of amphipathic-D (3 mg/kg twice daily). The results of all differential and biochemistry tests (i.e., tests for neutrophil, lymphocyte, monocyte, eosinophil, and basophil counts and creatine phosphokinase, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, and creatinine levels) were within the range of normal values. The Weizmann Institute Animal Protection Committee approved all the protocols used with the animal models. The animals had access to food and water throughout all experiments. Furthermore, the animals were acclimatized to our animal facilities for 1 week before the experiments began.
In summary, this study demonstrates that the activity of a diastereomer, but not an all-L-amino-acid antimicrobial peptide, was preserved in blood and that the peptide cured animals infected with bacteria (including a gentamicin-resistant strain). The data suggest that although the diastereomer initially in- teracts with the bacterial cell wall, it is mainly targeted toward the plasma membrane because (i) the potencies toward intact bacteria and spheroplasts were similar (Table 1) , (ii) the diastereomer depolarized the transmembrane potential of the bacteria at the same rate and concentration at which it showed biological activity, and (iii) the diastereomer acted similarly against both resistant and nonresistant bacteria. Although our data suggest that the protection of the mice was due to killing of the bacteria, previous studies have shown that positively charged antimicrobial peptides can bind to lipopolysaccharide (LPS) and neutralize the LPS-stimulated inflammatory response by macrophages (i.e., cytokine production) (10, 24) . It is possible, therefore, that the diastereomer further binds to and neutralizes the LPS released from the damaged bacteria.
Further advances need to be made in order to overcome the toxicities of such compounds. These may include modification of their sequences, injection of the peptide at a low concentration, or the use of delivery systems.
